Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS207 plus pemetrexed and platinum in driver-positive TKI-failed advanced non-squamous NSCLC
ChiCTR2500103512Phase 2Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- May 2025
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of JS207 in non-small cell lung cancer (NSCLC), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Investigator-assessed objective response rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
JS207
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500103512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103512.